New Delhi: The network of national scientists and community science movements have expressed concern for the World Health Organization that does not provide an emergency use list for ICMR-Bharat Biotech Covaxin.
It warns that India seems to depart to repeat the mistakes carried out in the Covaxin approval process in the way approve the Zycov-D vaccine three doses of Zydus Cadilla for 12 years and above.
As people who delay the permission for Covaxin who are looking for more technical details, the Indian Peoples science network says it is a serious setback for the Indian plan to distribute vaccines to other countries and for those who travel abroad that take Covaxin.
In a statement on Wednesday, Aipsn refers to the previous call for the disclosure of Covaxin trial data and said serious damage was carried out on India’s reputation with this defect application to WHO regulators “which also had the position of the Indian science and regulation system, which will now Come under international supervision and international suspicion “.
“The BB was applied to DCGI for EUA with inadequate data from the clinical trials that invited rejection, followed by arms behind the cried scene by the government that produced the provision of EUA.
The more detailed clinical clinical trial results were then released by bb with a reckless , Temporary results two months later and completed the trial data in June 2021, “said Aipsn.
Read Authorization of Alsowho Emergency Use for Covaxin Further Pending: Authorization of Emergency Use of Sourcesthe (EUA) for Covid-19 Vaccine Bharat Biotech, Covaxin is once again postponed by the World Health Organization, said the source.
The sources subsequently said that the UN public health agency has requested more data from Bharat Biotech for Covaxin.
Although criticized from scientists and others, Bharat Biotech has not published the results in the peer-reviewed journal after posting pre-publications.
paper.
It urges the center, ministries and departments to comply with scientific standards for conducting clinical trial results, publication results as a complete peer-reviewed article and transparency.